Unknown

Dataset Information

0

CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology.


ABSTRACT: We developed a SARS-CoV-2 vaccine candidate (CoV-RBD121-NP) comprised of a tobacco mosaic virus-like nanoparticle conjugated to the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 fused to a human IgG1 Fc domain. CoV-RBD121-NP elicits strong antibody responses in C57BL/6 mice and is stable for up to 12 months at 2-8 or 22-28 °C. Here, we showed that this vaccine induces a strong neutralizing antibody response in K18-hACE2 mice. Furthermore, we demonstrated that immunization protects mice from virus-associated mortality and symptomatic disease. Our data indicated that a sufficient pre-existing pool of neutralizing antibodies is required to restrict SARS-CoV-2 replication upon exposure and prevent induction of inflammatory mediators associated with severe disease. Finally, we identified a potential role for CXCL5 as a protective cytokine in SARS-CoV-2 infection. Our results suggested that disruption of the CXCL5 and CXCL1/2 axis may be important early components of the inflammatory dysregulation that is characteristic of severe cases of COVID-19.

SUBMITTER: DeMarco JK 

PROVIDER: S-EPMC8618284 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9327679 | biostudies-literature
| S-EPMC9220951 | biostudies-literature
| S-EPMC8921182 | biostudies-literature
| S-EPMC8402925 | biostudies-literature
| S-EPMC9032525 | biostudies-literature
| S-EPMC8295914 | biostudies-literature
| S-EPMC9783968 | biostudies-literature
| S-EPMC9450042 | biostudies-literature
| S-EPMC8955233 | biostudies-literature
| S-EPMC7832889 | biostudies-literature